Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 280

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Waldenstrom's macroglobulinaemia

Not recruiting

Study of CLR 131 for Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iopofosine (131I)
  • Sponsor:Cellectar Biosciences Inc.

Non-small cell lung cancer

Not recruiting

Study of AMG 193 and IDE397 for Adults with Advanced MTAP-null Solid Tumors and Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on the Safety and Effectiveness of AUTO1 for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Using a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Autolus Limited

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Sunvozertinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sunvozertinib
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia

Not recruiting

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Acute myeloid leukaemia recurrent

Not recruiting

Study of Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziftomenib
  • Sponsor:Kura Oncology Inc.

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Anaemia+1

Not recruiting

Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Universitaet Leipzig

Squamous cell carcinoma of head and neck+7

Not recruiting

Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut Gustave Roussy

Plasma cell myeloma

Not recruiting

Study of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Celgene Corp.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.